

**IN THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (previously presented) A method of improving the safety of patients receiving zonisamide treatment for epileptic seizures comprising:

providing a patient with a therapeutically effective amount of zonisamide,  
informing the patient that pancreatitis is a potential side effect of zonisamide treatment, and

informing the patient to seek immediate medical attention during the course of zonisamide treatment if the patient experiences one or more symptoms of pancreatitis; where the one or more symptoms of pancreatitis are selected from the group consisting of abdominal pain, shock, nausea, anorexia, vomiting, and abdominal distention.

2. (original) The method of claim 1, wherein the therapeutically effective amount of zonisamide is from 25 mg to 600 mg.

3. (original) The method of claim 2, wherein the therapeutically effective amount of zonisamide is provided in unit dose form.

4. (original) The method of claim 1, wherein the therapeutically effective amount of zonisamide is provided in a unit dose form and in multiple doses to provide for a course of therapy.

5. (original) The method of claim 4, wherein the unit dose is from 25 mg to 200 mg.

6. (previously presented) A method of managing the health of patients receiving zonisamide treatment for epileptic seizures comprising:

providing a patient with a therapeutically effective amount of zonisamide,

informing the patient that pancreatitis is a potential side effect of zonisamide treatment, and

informing the patient that during the course of zonisamide therapy, if (s)he experiences one or more symptoms chosen from the group of abdominal pain, shock, nausea, anorexia, vomiting, and abdominal distention, to seek immediate medical attention.

7. (original) The method of claim 6, wherein the therapeutically effective amount of zonisamide is from 25 mg to 600 mg.

8. (original) The method of claim 7, wherein the therapeutically effective amount of zonisamide is provided in unit dose form.

9. (original) The method of claim 6, wherein the therapeutically effective amount of zonisamide is provided in a unit dose form and in multiple doses to provide for a course of therapy.

10. (original) The method of claim 9, wherein the unit dose is from 25 mg to 200 mg.

11. (previously presented) A method of ameliorating a serious adverse event in a patient receiving zonisamide treatment for epileptic seizures comprising:

providing the patient with a therapeutically effective amount of zonisamide,  
informing the patient that pancreatitis is a potential side effect of zonisamide treatment,

and informing the patient that during the course of zonisamide therapy, if (s)he experiences one or more symptoms chosen from the group of abdominal pain, shock, nausea, anorexia, vomiting, and abdominal distention, to seek immediate medical attention.

12. (original) The method of claim 11, wherein the therapeutically effective amount of zonisamide is from 25 mg to 600 mg.

13. (original) The method of claim 12, wherein the therapeutically effective amount of zonisamide is provided in unit dose form.

14. (original) The method of claim 11, wherein the therapeutically effective amount of zonisamide is provided in a unit dose form and in multiple doses to provide for a course of therapy.

15. (original) The method of claim 14, wherein the unit dose is from 25 mg to 200 mg.

16.-31. (canceled)